Drug · Small Molecule
Etoposide
CI-DRUG-00000225Explore in graph →NCIt C491 CHEMBL44657 CIViC Approved
Regulatory
Approvals (18)
Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.
- Source
- openFDA — Drugs@FDA applications and drug labels (SPL)
- Dataset
- Drugs@FDA via openFDA
- Version
- drugsfda-2026-09-04
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- regulatory
- License
- CC0 1.0 Universal (public domain; https://open.fda.gov/license/)
- Run
- ING-OPENFDA-20260908-000001
| Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|
| US FDA | Malignant Testicular Neoplasm | Refractory testicular cancer | approved | Feb 13, 2026 | openfda |
| US FDA | Lung Small Cell Carcinoma | Small cell lung cancer | approved | Feb 13, 2026 | openfda |
| US FDA | — | Refractory testicular tumors, in combination with other chemotherapeutic drugs. | approved | May 17, 1996 | openfda |
| US FDA | Lung Small Cell Carcinoma | Small cell lung cancer, in combination with cisplatin, as first-line treatment. | approved | May 17, 1996 | openfda |
Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.
Data updated 2 days agoSource updated unknown
Derived
Development pipeline
Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.
| Scope | Stage | Max phase | Active | Recruiting | Phase 3 | Trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| All cancers | Approved | Phase 4 | 239 | 110 | 283 | 1,195 | 18 | CA, US | Dec 31, 1984 | 1988-03 |
| Malignant Lung Neoplasm | Approved | Phase 4 | 58 | 25 | 51 | 219 | 3 | US | Dec 30, 1986 | 1993-01 |
| Malignant Testicular Neoplasm | Approved | Phase 3 | 2 | 1 | 3 | 10 | 1 | US | Feb 13, 2026 | Nov 3, 2003 |
| Non-Hodgkin Lymphoma | Phase4 | Phase 4 | 48 | 20 | 30 | 200 | 0 |
Curated evidence
Clinical evidence (10)
CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 15659725
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| NPM1 W288FS1 | ||||||||
| Cytarabine + Daunorubicin | ||||||||
Clinical trials
Trials with this intervention (1,198)
Most recently updated first, 50 per page.
- Source
- ClinicalTrials.gov
- Dataset
- ClinicalTrials.gov API v2 studies
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00004905 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Acute Leukemia | completed | Phase 2 | — | Loyola UniversityOTHER | 1 | May 30, 2013 | clinicaltrials |
| NCT00004906 | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer | completed |